NCT07633015已完成不适用
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Empagliflozin/Metformin in 5 mg / 850 mg Tablets in Healthy Subjects Under Fed Conditions.
ADIUM1 个研究点 分布在 1 个国家目标入组 42 人开始时间: 2025年2月17日最近更新:
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 42
- 试验地点
- 1
研究概览
简要总结
Prospective, longitudinal, single-dose, randomized, open-label, crossover 2x2, two treatments, two periods, two sequences controlled clinical study
详细描述
The study design was a randomized, open-label, two-way, crossover, single-dose, prospective, and longitudinal study, with a 14-day wash-out period before next dosing; to compare the pharmacokinetic profile (Cmax and AUC0-t) of two 5/ 850 mg empagliflozin/metformin FDC tablet in forty-two (42) healthy Mexican adult volunteers aged 18 to 55 years.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Health Services Research
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Age between 18 and 55 years.
- •Clinically healthy according to the updated medical history prior to the start of the study.
- •Not blocked in the COFEPRIS research subject database.
- •Body mass index between 18 and 27 kg/m².
- •Normal vital signs: Heart rate between 60 and 99 beats per minute, respiratory rate between 12 and 20 breaths per minute, systolic blood pressure between 90-130 mmHg, diastolic blood pressure between 60-89 mmHg, and temperature between 36.0 and 37.4°C.
- •Electrocardiogram (ECG) without any signs of pathology.
- •Clinical laboratory test results within normal limits or with clinically insignificant variations.
- •Negative biosafety tests for the presence of human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), and varicella-zoster virus (VDRL).
- •Negative drug screening tests for amphetamines, benzodiazepines, cocaine, methamphetamines, morphine, and tetrahydrocannabinol (THC).
- •Negative qualitative pregnancy test (for women).
- •Negative breath alcohol test.
- •Research subjects with no history of alcohol abuse or dependence, psychoactive substance abuse, or chronic medication use.
- •Subjects with a signed informed consent form and a signed non-pregnancy commitment letter.
- •Women who are not pregnant or breastfeeding.
- •Women using at least one method of family planning deemed safe by the principal investigator.
排除标准
- •Subjects with a history of hypersensitivity to the study drug.
- •Subjects with lactose intolerance.
- •Subjects with a history of cardiovascular, renal, hepatic, metabolic, gastrointestinal, neurological, endocrine, hematopoietic (any type of anemia), mental illness, or other organic abnormalities that could affect the pharmacokinetic study of the study product.
- •Subjects requiring any medication during the course of the study that interferes with the quantification or pharmacokinetics of the study drug.
- •Subjects who have been exposed to agents known to induce or inhibit hepatic enzyme systems or who have taken potentially toxic medications within 30 days prior to the start of the study.
- •Subjects who, prior to receiving the study drug, have taken medications such as those described in section 3.11 "Drug Interactions."
- •Subjects who have been hospitalized for any reason within sixty days prior to the start of the study or who have been seriously ill within thirty days prior to the start of the study.
- •Subjects who have received an investigational drug within ninety days prior to the start of the study.
- •Subjects who have donated or lost 450 mL or more of blood within sixty days prior to the start of the study.
- •Research subjects with a history of alcohol or psychoactive substance abuse or dependence, or chronic medication use.
- •Subjects who have consumed beverages or foods containing xanthines (coffee, tea, cocoa, chocolate, yerba mate, cola, etc.) or have consumed charcoal-grilled foods within 12 hours prior to administration of the medication dose.
- •Subjects who have consumed grapefruit, cranberry, or pomegranate juice within 12 hours prior to the study.
- •Subjects who have smoked at least 12 hours before the start of the study.
- •Subjects who have ingested alcoholic beverages 48 hours prior to administration of the dose.
- •Positive (qualitative) pregnancy test.
研究组 & 干预措施
Synjardy 5/850 mg tablet, Reference
Active Comparator
Reference. Empagliflozin/metformin 5/850 mg tablet
干预措施: Synjardy 5/850 mg tablet, Reference (Drug)
Empagliflozin/metformin 5/850 mg test
Experimental
Test. Empagliflozin/metformin 5/850 mg
干预措施: Test. Empagliflozin/metformin 5/850 mg (Drug)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
Study to evaluate the bioequivalence and safety of Etonogestrel Implant in Healthy Female ParticipantsCTRI/2024/08/072277Loop Therapeutics LLC310
已完成
不适用
Bioequivalence study between Semaglutide injection 2mg/1.5mL with Wegovy in adult human subjects under fasting conditions.CTRI/2025/07/090224Cipla Ltd India40
尚未招募
不适用
A Clinical to Compare Two Iron Medicines for Treating Iron Deficiency Anaemia in AdultsCTRI/2025/09/093973AFT Pharmaceutical240
招募中
1 期
Bioequivalence Study of GZR18 Injection Before and After CMC ChangeNCT07355738Gan & Lee Pharmaceuticals.138
尚未招募
不适用
BIOEQUIVALENCE STUDY OF SEMAGLUTIDE INJECTION 8 mg/3 mL (Dose:2 mg) - FASTINGCTRI/2025/11/097878Virchow Biotech Private Limited68